Involvement of TACE in colon inflammation: A novel mechanism of regulation via SIRT-1 activation

Sharma, Manoranjan; Mohapatra, Jogeswar; Wagh, Akshaya; Patel, Hiren; Pandey, Dheerendra; Kadam, Shekhar; Argade, Anil; Deshpande, Shrikalp; Shah, Gourang B.; Chatterjee, Abhijit; Jain, Mukul

doi:10.1016/j.cyto.2013.12.010

Cited by 36 publications

(23 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We selected a novel TACE inhibitor, compound 11p, which is potent and highly selective (nearly 500-fold) for TACE over other MMPs and ADAM family members 28 . In a very recent study, we have demonstrated the antiinflammatory effect of compound 11p in colon inflammation 29 .…”

Section: Discussionmentioning

confidence: 99%

Chemopreventive effect of a novel, selective TACE inhibitor on DMBA- and TPA-induced skin carcinogenesis

Sharma¹,

Mohapatra²,

Argade

et al. 2014

Immunopharmacology and Immunotoxicology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Chemopreventive effect of a novel, selective TACE inhibitor on DMBA- and TPA-induced skin carcinogenesis

Sharma¹,

Mohapatra²,

Argade

et al. 2014

Immunopharmacology and Immunotoxicology

Self Cite

View full text Add to dashboard Cite

show abstract

“…TIMP-3 is the endogenous inhibitor of TACE and is positively associated with silent information regulator (SIRT)-1. After induction of colitis via DSS administration, the expression of TACE was increased, whereas TIMP-3 and SIRT-1 mRNA levels were decreased (Sharma et al, 2014).…”

Section: Involvement Of Mmps and Timps In Animal Models Of Colitismentioning

confidence: 96%

The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases

Bruyn¹,

Vandooren

Ugarte-Berzal

et al. 2016

Critical Reviews in Biochemistry and Molecular Biology

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are thought to be predominant proteases and protease inhibitors involved in the pathogenesis of inflammatory bowel diseases (IBD) through their ability to remodel the extracellular matrix (ECM) in response to inflammatory stimuli and by their immunomodulating effects. An imbalance between MMPs and TIMPs has been linked with acute and chronic inflammation and aberrant tissue remodeling, as seen in IBD. Moreover, recurrent phases of tissue destruction and subsequent tissue repair can cause serious complications in IBD patients such as fistulas and fibrosis. The aims of this review are (i) to summarize current literature on genetic association, mRNA, and protein expression studies with regard to MMPs and TIMPs in IBD patients and various animal models, including those with transgenic and knockout mice; (ii) to compare biochemical and molecular biological data in humans with those obtained in animal model studies and (iii) to critically evaluate and translate how this knowledge may be used in practical terms to understand better the pathophysiology and mechanisms operating in IBD and to apply this for improvement of clinical outcomes at diagnostic, prognostic and therapeutic levels.

show abstract

“…5) Previous research has demonstrated that resveratrol has anti-inflammatory and anti-oxidant activity. 6) In vitro and in vivo studies have confirmed that resveratrol can ameliorate IBD by reducing mucosal inflammation, 7,8) however, the specific mechanism by which resveratrol works is currently unclear.…”

Section: Introductionmentioning

confidence: 99%

Resveratrol Attenuates Inflammatory Bowel Disease in Mice by Regulating SUMO1

Wang

Zhang²,

Fang

et al. 2020

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Resveratrol (Res) is a natural active antioxidant that is effective in relieving inflammatory bowel disease (IBD). However, the specific mechanism for its function is unknown. In our study, dextran sodium sulfate (DSS)-induced mouse IBD disease model was constructed. All mice were randomly divided into three groups. The treatment effects of resveratrol on IBD were evaluated by observing the body weight, fecal traits, colon/ spleen gross appearance, tissue hematoxylin-eosin (H&E)/immunohistochemistry (IHC) and inflammatory factors. The expression of small ubiquitin-like modifier protein 1 (SUMO1) and its Wnt/β-catenin pathwayrelated genes was analyzed by IHC, Western blot, Real-time PCR (RT-PCR) and Immunofluorescence. The outcome indicated that resveratrol treatment significantly relieved the symptoms of IBD. The expression level of anti-inflammatory cytokines was increased while that of pro-inflammatory cytokines was decreased in both colon and spleen tissues of resveratrol-treated mice. SUMO1 expression and Wnt/β-catenin pathway were suppressed in colon and spleen tissues of IBD mice treated with resveratrol. In addition, we provided evidence that resveratrol inhibited SUMO1 and β-catenin expression and their nuclear localization in human colonic epithelial cell line (FHC). Moreover, we found that SUMO1 and β-catenin had higher expression levels in colorectal cancer patients than in health and colitis patients. In conclusions, resveratrol alleviates DSSinduced IBD by modulating SUMO1 through Wnt/β-catenin pathway.

show abstract

Involvement of TACE in colon inflammation: A novel mechanism of regulation via SIRT-1 activation

Cited by 36 publications

References 41 publications

Chemopreventive effect of a novel, selective TACE inhibitor on DMBA- and TPA-induced skin carcinogenesis

Chemopreventive effect of a novel, selective TACE inhibitor on DMBA- and TPA-induced skin carcinogenesis

The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases

Resveratrol Attenuates Inflammatory Bowel Disease in Mice by Regulating SUMO1

Contact Info

Product

Resources

About